2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2342

Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Abstract Number: 2343

Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Abstract Number: 2344

A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Abstract Number: 2345

Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Abstract Number: 2346

Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1b Production through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells
Abstract Number: 2347

Can We Predict the Dose of Allopurinol to Achieve Target Urate?
Abstract Number: 2349

The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Abstract Number: 2350

Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study
Abstract Number: 2351

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Abstract Number: 2352

Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Abstract Number: 2353

Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Abstract Number: 2354

The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Abstract Number: 2355

Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial
Abstract Number: 2356

Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
Abstract Number: 2357

Xanthine Oxidase Inhibitors for the Prevention of Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].